Compare Ascendis Pharma A/S (ASND) vs Packaging Corporation of America (PKG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Packaging Corporation of America — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Packaging Corporation of America trades at $228.77 (market cap $20.38B). The key difference: Ascendis Pharma A/S and Packaging Corporation of America are close in size by market cap, and Packaging Corporation of America pays a 2.62% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | PKG | |
|---|---|---|
Market Cap | $17.74B | $20.38B |
Sector | Health | Technology |
52-Week High | $277.18 | $246.31 |
52-Week Low | $163.32 | $191.41 |
Enterprise Value | $18.11B | $24.21B |
Dividend Yield | — | 2.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
Packaging Corporation of America (PKG) trades at $228.77, up 1.91% with a bullish technical signal. The company reported mixed Q1 2026 earnings with $2.40 EPS beating estimates, though revenue growth faces margin pressure. Analyst consensus is mixed with 34.6% buy ratings and a $253 price target. Recent 20% dividend increase signals management confidence amid elevated input costs.
PKG offers steady dividend income with potential upside to analyst targets, but faces headwinds from cost inflation and competitive pressures. The stock's 27.8 P/E suggests full valuation, requiring sustained earnings growth to justify current levels. Near-term performance hinges on Q2 results and operational efficiency improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Packaging Corporation of America
Packaging Corporation of America is a leading producer of containerboard and corrugated packaging products in North America. The company also produces white papers, which include printing and writing papers. PKG operates as an integrated manufacturer, with a strong focus on high-quality and sustainable packaging solutions for e-commerce, food and beverage, and other industrial and consumer markets.
Read more on PKG →
